Ortin Global Ltd

Ortin Global Limited: Trading Window closed from 01.10.2026 till 48 hours after the declaration of Unaudited Financial Results for the quarter and half-year ended 30.09.2026

Financial highlights

• Revenue from operations declined to 10.05 Lakhs in 2025-26.
• Total revenue was 41.50 Lakhs in 2025-26 vs 38.35 Lakhs prior year.
• Net loss after tax: 74.04 Lakhs in 2025-26.
• EPS: -0.91 for 2025-26.
• RoNW: -62.28% in 2025-26.
• Net cash from operating activities: -55.96 Lakhs in 2025-26.

Capital structure & liquidity

• Borrowings (non-current) stood at 100.50 Lakhs.
• Equity share capital as at 31-03-2026: 813.14 Lakhs.
• Cash & cash equivalents: 60.59 Lakhs.
• Net worth: negative 689.43 Lakhs.

Promoter & open offer

• Open offer period: June 5–18, 2026 for up to 21,14,162 shares.
• Promoter holding changed to 1.24% post open offer.
• Promoter Sellers ceased to hold equity; Parveen Satija promoted/control increased.

Board changes & governance

• Murali Krishna Murthy Sanka moved from MD to Non-Executive Director on 07.09.2026.
• Prashant Prakash Sawant designated as Managing Director from 07.09.2026; nil remuneration.
• Parveen Satija appointed Whole-time Director from 07.09.2026 at Rs50,000/month.
• Board meetings totaled eight in FY2025-26.
• Independent directors declared independence; no material conflicts.

Audit & internal controls

• Statutory auditors issued an unmodified report for FY2025-26.
• Secretarial audit flagged non-appointment of internal auditor for FY2025-26.
• Penalty paid for late appointment of Company Secretary: Rs 56,000 plus GST.
• Internal controls deemed adequate and operating.

Related party transactions

• Related party transactions are arm's length and in the ordinary course.
• Tansimed Innovatives: purchases 0.90 Lakhs; sales 7.23 Lakhs.
• Unsecured loan to Pramod Waghe: 80.50 Lakhs.

Subsidiaries & operations

• Company has no subsidiaries, associates, or joint ventures.
• The company operates in pharmaceutical trading and related activities.

Outlook & risks

• Indian pharma outlook remains positive; company focuses on expansion and profitability.

Director resignation

• Prakruti Prashant Sawant resigns as Whole-time Director with effect from 07.09.2026 (DIN:11162997).

Key board changes

• Murali Krishna Murthy Sanka designated from Managing Director to Non-Executive Director, effective 07.09.2026, subject to member approval.
• Sawant designated from Whole-time Director to Managing Director for 3 years, effective 07.09.2026, subject to member approval.
• Prakruti Prashant Sawant resigns from Whole-time Director, effective 07.09.2026.
• Parveen Satija appointed as Additional Director and Whole-time Director for 2 years, effective 07.09.2026, subject to member approval.

Governance and AGM

• 39th Directors Report for FY2025-26 and AGM notice prepared.
• 39th AGM for FY2025-26 scheduled for 30 September 2026 via video conference or OAVM.

Q1 FY27 highlights

• Net sales/income from operations for Q1 ended 30.06.2026: 1.16.
• Other operating income: 0.44 for the quarter.
• Total income (1+2) for the quarter: 1.60.
• Total expenses for the quarter: 35.06.
• Profit before tax: -33.46; tax deferred: 0.33.
• Profit after tax: -33.79.
• EPS (basic/diluted) before extraordinary items: -0.42.
• EPS after extraordinary items: -0.42.
• Paid-up equity share capital: 813.14.

Notes & auditor comments

• Unaudited results prepared in Ind AS; limited review performed.
• Company operates in a single segment; segment reporting not applicable.
• Auditors’ limited review concluded no material misstatement.
• Other Equity balance shown as (689.43) as of 31.03.2026.

Meeting Details

• Board meeting scheduled for 14 August 2026 at the registered office in Hyderabad.
• Time of meeting not disclosed.

Key Agenda Items

• Unaudited financial results for the quarter ended 30 June 2026 with Limited Review Report.
• Any other business with permission of the Chair.

Other Notes

• Trading window closed from 01 July 2026 until 48 hours after the unaudited Q1 2026 results.

Dematerialisation/rematerialisation status

• RTA-certified details of dematerialised/rematerialised securities furnished to all stock exchanges.
• Details cover securities dematerialised/rematerialised during the reporting period.

Open offer details

• Post-offer advertisement filed by Rarever Financial Advisors Private Limited for Acquirer Parveen Satija.
• Open offer: 21,14,162 equity shares, 26% of Ortin Global, at ₹14.65 per share.
• Period: open 5 June 2026 to 18 June 2026; payment of consideration by 3 July 2026.
• Acquirer pre-offer stake: Nil; post-offer shareholding proposed: 26%.
• Aggregate offer size: ₹3.10 crore.
• Tendered vs accepted: 226 tendered; 21,14,162 shares accepted.
• Acquirer accepts responsibility for information in the Post Offer Advertisement.
• Registrar to the offer: Bigshare Services Private Limited.
• Manager to the offer: Rarever Financial Advisors Private Limited; Acquirer: Parveen Satija.

Open offer

• Acquirer: Mr. Parveen Satija.
• Target company: Ortin Global Limited.
• Offer triggered by proposed open offer to public shareholders.

Offer terms

• Up to 21,14,162 equity shares will be acquired.
• Shares represent 26.00% of voting share capital.
• Offer price is ₹14.65 per share.
• Consideration will be paid in cash.
• Offer is a mandatory open offer.

Timeline

• Identified date for letter of offer dispatch is May 21, 2026.
• Public announcement was made earlier, followed by detailed public statement and draft letter of offer.